Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.37 |
| ▸ | CTRB1 | P17538 | 5/20 | 0.36 |
| ▸ | PLA2G2C | Q5R387 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CRAT | P43155 | 1/20 | 0.34 |
| ▸ | GRB2 | P62993 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.30 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8223698 | 0.85 | — | — | |
| SCHEMBL10940119 | 0.75 | GABRR1 (0.43) | DNM1PLA2G2CKDM4EMAPTTHRB | |
| Trifluoroacetic Acid SCHEMBL29695793 | 0.74 | MLYCD (0.41) | CTRB1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL12583585 | 0.74 | — | — | |
| SCHEMBL20244940 | 0.74 | — | — | |
| SCHEMBL19464383 | 0.74 | — | — | |
| Trifluoroacetic Acid SCHEMBL2475408 | 0.73 | CACNA2D1 (0.41) | — | |
| Trifluoroacetic Acid SCHEMBL15664323 | 0.73 | ESR1 (0.31) | — | |
| SCHEMBL13696409 | 0.72 | — | — | |
| Trifluoroacetic Acid SCHEMBL27567846 | 0.72 | CETP (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044072-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | AstraZeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| US-20080214577-A1 | New Compounds 320 | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-20080058349-A1 | New Compounds 318 | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| WO-2007145571-A1 | AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214577-A1 | New Compounds 320 | PSEN1, PSEN2, MAPT | DNM1 563/4885CTRB1 2962/4885PLA2G2C 572/4885 |
| US-20080058349-A1 | New Compounds 318 | PSEN2, PSEN1, MAPT | DNM1 552/4885CTRB1 3273/4885PLA2G2C 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.